Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Regulation, ethics review and informed consent

Regulatory and ethics approvals in Uganda and the region

13 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • List the approvals a clinical trial typically needs in Uganda

  • Explain the roles of the research ethics committee, the national council and the drug regulator

  • Describe the submission, review, amendment and continuing review cycle

Every clinical trial needs permission from several independent bodies before the first participant is enrolled. The exact requirements change over time and differ by country, so teams must always check the current rules. This lesson describes the typical pattern in Uganda as a guide.

Typical approvals for a trial of a medicine or vaccine

  • Research ethics committee (REC) approval: an institutional or independent REC accredited to review human research reviews the protocol, consent forms, investigator qualifications, recruitment materials and budget. Many institutions have their own RECs, such as university and hospital committees.
  • Uganda National Council for Science and Technology (UNCST) registration: research involving human participants must be registered with the national council, which also oversees research regulation and, for foreign researchers, additional permissions.
  • National Drug Authority (NDA) authorisation: clinical trials of medicines, vaccines and some devices need regulatory approval, including import permits for investigational products and review of safety reports.
  • Local permissions: district health officers and local leaders where the study takes place.
  • Trial registration: registering the trial in a public registry such as the Pan African Clinical Trials Registry or ClinicalTrials.gov before the first participant is enrolled, as required by the ICMJE for later publication.
1ProtocolreadyProtocol,consent,brochure2REC reviewIndependentethics approval3UNCST and NDARegistration,authorisation4Registry andlocalTrial registry,district5StartenrolmentOnly after allapprovals
A typical approval pathway. Sequence and requirements vary, so always confirm current rules.

What a REC reviews

  • Scientific validity and the question's importance.
  • Risks and benefits and how they are minimised.
  • Selection of participants and fair recruitment.
  • The consent process and documents, in language participants understand.
  • Privacy and confidentiality, including data protection under the Data Protection and Privacy Act, 2019.
  • Compensation and treatment for injury, payments and incentives (which must not be coercive).
  • Qualifications of the investigators and suitability of the site.
  • Community engagement and post-trial plans.

After approval

Approval is not permanent. The protocol team must:

  • Submit amendments before implementing changes (except to eliminate immediate hazards).
  • Submit safety reports as required, such as serious unexpected events.
  • Submit progress reports and apply for annual continuing review, which lapses if not renewed.
  • Report deviations and violations, and inform the REC of early termination.
  • Provide a final report and, where required, share results with participants and the community.

Worked example: a timeline for start-up approvals

A sponsor plans a phase II trial in a district hospital. The study team prepares a realistic timeline.

  • Week 0 to 4: finalise protocol, consent documents, investigator brochure and budget.
  • Week 4 to 10: submit to the REC. Meetings occur monthly, so a response may come in 4 to 6 weeks, then queries must be answered.
  • Week 10 to 14: register with UNCST and apply to the NDA.
  • Week 14 to 18: import permit for the study drug, site initiation preparations.

The team therefore plans for about four to six months before the first participant, longer if queries are slow. A sponsor who promises enrolment in two months is not planning realistically.

Week 0Documents finalWeek 10REC responseWeek 14National approvalsWeek 18Import permit, sitereadyWeek 20+Enrol firstparticipant
An illustrative start-up timeline. Real timelines depend on committee calendars and the quality of submissions.

Submit complete and consistent packages

Most delays come from incomplete files, inconsistent documents (protocol and consent do not match) or missed meeting deadlines. A checklist and one person responsible for regulatory affairs shorten approval time.

Never start before approval

Screening, recruitment, or any study procedure before all required approvals is a serious violation. Pre-screening using only routine records may be allowed if the REC says so; confirm in writing.

Check yourself

List every approval your current or planned study needs, who grants it, how often they meet and how long renewal takes. Put the renewal dates in a shared calendar.

Summary

  • Trials need REC approval, national registration, regulatory authorisation and trial registry entry before enrolment.

  • RECs review science, risk, consent, privacy, compensation and investigator qualifications.

  • Approval continues through amendments, safety reports, annual review and final reporting.

  • Plan realistic start-up timelines of months, not weeks.

Check your understanding

Question 1
1

Which body registers research involving human participants in Uganda?

Question 2
2

The regulator that authorises trials of medicines and vaccines in Uganda is the:

Question 3
3

Changes to an approved protocol should normally be:

Question 4
4

Annual continuing review is needed because:

Question 5
5

A major cause of start-up delay is:

Question 6
6

Trial registration in a public registry should occur:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

The drug development pathway and trial phasesInformed consent that is genuinely informed